MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciaf007

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025

Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM).

Barbosa Laila, Brito-Sousa José, Nascimento Cristiana, Pacheco Ana, Alexandre Márcia, Alencar Aline, Melo Marly, Omena Aretha, Souza Ingrid, Silva Emanuelle, Queiroz Michael, Siqueira Vitória, Rabelo Cristina, Baía-da-Silva Djane, Silva Débora, Rocha Yasmin, Barbosa Antônio, Castro Ramon, Almeida Anne, Brito Marcelo, Lopes Adriana, Balieiro Antônio, Costa Mônica, Amaral Thais, Valle Cristiane, Vieira Alexia, Gonzaga Jhon, Pereira Dhélio, Alecrim Maria, Monteiro Wuelton, Lacerda Marcus, Melo Gisely

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Daily primaquine-induced hemolysis is a common cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-phosphate dehydrogenase deficiency (G6PDd). Alternative regimens balancing safety and efficacy are needed.

METHODS

G6PDd participants with P. vivax malaria from 2 sites in Brazilian Amazon between 2018 and 2022 were randomly allocated to 3 arms that received chloroquine (CQ) from day 1 to day 3 plus (arm 1) a 7-day course of primaquine (PQ) (0.5 mg/kg/day), beginning at day 5; (arm 2) weekly PQ over 8 weeks (0.75 mg/kg/wk); or (arm 3) weekly CQ over 12 weeks (5 mg/kg/wk). A normal-G6PD participants group was also enrolled in parallel using CQ for 3 days plus PQ for 7 days. The primary focus was safety profile; secondary was the number of patients free from the first recurrence until day 180.

RESULTS

Fifty-four G6PDd participants were enrolled. There were 2 participants in arm 1, but the arm was halted due to safety concerns. The weekly PQ group presented higher hemoglobin decreases in day 3 after first dose (Δhemoglobin = -1.61) than the weekly CQ group (Δhemoglobin = -0.99), but efficacy was superior over the 6-month follow-up.

CONCLUSIONS

Postponing the beginning of daily PQ to day 5, when less oxidative stress related to malaria itself would, in theory, decrease hemolytic effects of the drug in G6PDd patients, was not shown to be safe. Weekly CQ avoiding the first relapse did not stop further relapses. Weekly PQ, as already demonstrated in Southeast Asia, was equally safe and efficacious in patients from Latin America. Clinical Trials Registration. NCT03529396.

Для цитирования: Barbosa Laila, Brito-Sousa José, Nascimento Cristiana, Pacheco Ana, Alexandre Márcia, Alencar Aline, Melo Marly, Omena Aretha, Souza Ingrid, Silva Emanuelle, Queiroz Michael, Siqueira Vitória, Rabelo Cristina, Baía-da-Silva Djane, Silva Débora, Rocha Yasmin, Barbosa Antônio, Castro Ramon, Almeida Anne, Brito Marcelo, Lopes Adriana, Balieiro Antônio, Costa Mônica, Amaral Thais, Valle Cristiane, Vieira Alexia, Gonzaga Jhon, Pereira Dhélio, Alecrim Maria, Monteiro Wuelton, Lacerda Marcus, Melo Gisely. Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM).. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025. DOI: 10.1093/cid/ciaf007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.